Why Teradyne Stock Soared 18.9% Today
The company reported its Q2 earnings, beating most of Wall Street's targets.
Guidance for Q3 EPS missed forecasts, but revenue projections suggest a second-half rebound driven by AI.
10 stocks we like better than Teradyne ›
Shares of Teradyne (NASDAQ: TER) jumped on Wednesday, finishing the day up 18.9%. The spike comes as the S&P 500 (^GSPC) and the Nasdaq Composite (^IXIC) fell slightly.
Teradyne, an electronics testing company, released mostly better-than-expected earnings today, leading to a prominent analyst maintaining their "overweight" rating for the stock.
Teradyne beats in the second quarter (mostly)
The company's reported earnings per share (EPS) and revenue figures both slightly topped expectations. Analysts had estimated $0.54 per share on sales of $651 million. Teradyne delivered $0.57 per share on sales of $651 million. While the company surpassed expectations for the quarter, its top line fell by 11% year over year (YOY).
Looking ahead, the company expects sales for Q3 of between $710 million and $770 million, above Wall Street targets. It did miss, however, on its EPS guidance. The company set a range of between $0.69 and $0.87, well below the expected $0.89.
CEO Greg Smith said he expects AI-related testing to drive growth: "As we progress through the third quarter, we are gaining confidence in AI compute-related revenue inflecting in the second half of the year."
Teradyne has room to grow
Impressed by the performance and not phased by the lower-than-expected earnings guidance, Cantor Fitzgerald analysts maintained their Overweight rating, citing AI growth prospects. I agree. I think AI-related chip testing could drive major growth over the next few years.
Should you invest $1,000 in Teradyne right now?
Before you buy stock in Teradyne, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teradyne wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!*
Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Teradyne. The Motley Fool has a disclosure policy.
Why Teradyne Stock Soared 18.9% Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street's revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company's full-year revenue guidance of $875 million at the midpoint came in 2.7% below analysts' estimates. Its GAAP profit of $0.29 per share was 28.4% above analysts' consensus estimates. Is now the time to buy Corcept? Find out in our full research report. Corcept (CORT) Q2 CY2025 Highlights: Revenue: $194.4 million vs analyst estimates of $201.5 million (18.7% year-on-year growth, 3.5% miss) EPS (GAAP): $0.29 vs analyst estimates of $0.23 (28.4% beat) The company dropped its revenue guidance for the full year to $875 million at the midpoint from $925 million, a 5.4% decrease Operating Margin: 13.7%, down from 21.7% in the same quarter last year Market Capitalization: $7.41 billion 'The second quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a record number of new prescribers and a record number of new patients receiving treatment. Physicians increasingly recognize hypercortisolism's true prevalence and the necessity of appropriate treatment, which has led to increased screening and diagnosis. Our financial results don't fully reflect this surge in demand, which outpaced our specialty pharmacy vendor's capacity. We expect improved performance by our current vendor, as well as contribution from a second pharmacy that is coming online soon, in the coming quarters and have modified our 2025 revenue guidance to $850 – $900 million,' said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. Company Overview Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Corcept grew its sales at a solid 15.3% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Corcept's annualized revenue growth of 29.3% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. This quarter, Corcept's revenue grew by 18.7% year on year to $194.4 million but fell short of Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 85.1% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and indicates its newer products and services will spur better top-line performance. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Corcept has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 23.1%. Looking at the trend in its profitability, Corcept's operating margin decreased by 16.9 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 8.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Corcept generated an operating margin profit margin of 13.7%, down 8 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Corcept's EPS grew at an unimpressive 3.9% compounded annual growth rate over the last five years, lower than its 15.3% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes. Diving into the nuances of Corcept's earnings can give us a better understanding of its performance. As we mentioned earlier, Corcept's operating margin declined by 16.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, Corcept reported EPS at $0.29, down from $0.32 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Corcept's full-year EPS of $1.13 to grow 53.5%. Key Takeaways from Corcept's Q2 Results We were impressed by how significantly Corcept blew past analysts' EPS expectations this quarter. On the other hand, its revenue missed and its full-year revenue guidance fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 3.7% to $64.50 immediately following the results. Corcept may have had a tough quarter, but does that actually create an opportunity to invest right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Monolithic Power Systems (NASDAQ:MPWR) Surprises With Q2 Sales, Provides Optimistic Revenue Guidance for Next Quarter
Power management chips maker Monolithic Power Systems (NASDAQ:MPWR) announced better-than-expected revenue in Q2 CY2025, with sales up 31% year on year to $664.6 million. On top of that, next quarter's revenue guidance ($720 million at the midpoint) was surprisingly good and 5.7% above what analysts were expecting. Its non-GAAP profit of $4.21 per share was 2.2% above analysts' consensus estimates. Is now the time to buy Monolithic Power Systems? Find out in our full research report. Monolithic Power Systems (MPWR) Q2 CY2025 Highlights: Revenue: $664.6 million vs analyst estimates of $652.1 million (31% year-on-year growth, 1.9% beat) Adjusted EPS: $4.21 vs analyst estimates of $4.12 (2.2% beat) Adjusted Operating Income: $231.2 million vs analyst estimates of $226.4 million (34.8% margin, 2.1% beat) Revenue Guidance for Q3 CY2025 is $720 million at the midpoint, above analyst estimates of $681 million Operating Margin: 24.8%, up from 23% in the same quarter last year Inventory Days Outstanding: 150, up from 146 in the previous quarter Market Capitalization: $34.98 billion 'Our proven, long-term growth strategy remains intact as we continue our transformation from being a chip-only, semiconductor supplier to a full service, silicon-based solutions provider,' said Michael Hsing, CEO and founder of MPS. Company Overview Founded in 1997 by its longtime CEO Michael Hsing, Monolithic Power Systems (NASDAQ:MPWR) is an analog and mixed signal chipmaker that specializes in power management chips meant to minimize total energy consumption. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Monolithic Power Systems's 29.9% annualized revenue growth over the last five years was incredible. Its growth surpassed the average semiconductor company and shows its offerings resonate with customers, a great starting point for our analysis. Semiconductors are a cyclical industry, and long-term investors should be prepared for periods of high growth followed by periods of revenue contractions (which can sometimes offer opportune times to buy). We at StockStory place the most emphasis on long-term growth, but within semiconductors, a half-decade historical view may miss new demand cycles or industry trends like AI. Monolithic Power Systems's annualized revenue growth of 17.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. This quarter, Monolithic Power Systems reported wonderful year-on-year revenue growth of 31%, and its $664.6 million of revenue exceeded Wall Street's estimates by 1.9%. Beyond the beat, this marks 6 straight quarters of growth, showing that the current upcycle has had a good run - a typical upcycle usually lasts 8-10 quarters. Company management is currently guiding for a 16.1% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 10.1% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is commendable and implies the market sees success for its products and services. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Product Demand & Outstanding Inventory Days Inventory Outstanding (DIO) is an important metric for chipmakers, as it reflects a business' capital intensity and the cyclical nature of semiconductor supply and demand. In a tight supply environment, inventories tend to be stable, allowing chipmakers to exert pricing power. Steadily increasing DIO can be a warning sign that demand is weak, and if inventories continue to rise, the company may have to downsize production. This quarter, Monolithic Power Systems's DIO came in at 150, which is 12 days below its five-year average. These numbers show that despite the recent increase, there's no indication of an excessive inventory buildup. Key Takeaways from Monolithic Power Systems's Q2 Results It was great to see Monolithic Power Systems's revenue guidance for next quarter top analysts' expectations. We were also happy its adjusted operating income outperformed Wall Street's estimates. On the other hand, its inventory levels increased. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 4.9% to $747.50 immediately after reporting. Indeed, Monolithic Power Systems had a rock-solid quarterly earnings result, but is this stock a good investment here? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
22 minutes ago
- Yahoo
ICF International (NASDAQ:ICFI) Misses Q2 Revenue Estimates
Professional consulting firm ICF International (NASDAQ:ICFI) fell short of the market's revenue expectations in Q2 CY2025, with sales falling 7% year on year to $476.2 million. Its non-GAAP profit of $1.66 per share was 5.2% above analysts' consensus estimates. Is now the time to buy ICF International? Find out in our full research report. ICF International (ICFI) Q2 CY2025 Highlights: Revenue: $476.2 million vs analyst estimates of $481.1 million (7% year-on-year decline, 1% miss) Adjusted EPS: $1.66 vs analyst estimates of $1.58 (5.2% beat) Adjusted EBITDA: $52.88 million vs analyst estimates of $51.44 million (11.1% margin, 2.8% beat) Operating Margin: 8.4%, in line with the same quarter last year Free Cash Flow Margin: 9.7%, down from 10.8% in the same quarter last year Backlog: $3.4 billion at quarter end Market Capitalization: $1.52 billion Company Overview Operating at the intersection of policy, technology, and implementation for over five decades, ICF International (NASDAQ:ICFI) provides professional consulting services and technology solutions to government agencies and commercial clients across energy, health, environment, and security sectors. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. With $1.98 billion in revenue over the past 12 months, ICF International is a mid-sized business services company, which sometimes brings disadvantages compared to larger competitors benefiting from better economies of scale. On the bright side, it can still flex high growth rates because it's working from a smaller revenue base. As you can see below, ICF International grew its sales at a decent 5.9% compounded annual growth rate over the last five years. This shows its offerings generated slightly more demand than the average business services company, a useful starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within business services, a half-decade historical view may miss recent innovations or disruptive industry trends. ICF International's recent performance shows its demand has slowed as its annualized revenue growth of 1.3% over the last two years was below its five-year trend. ICF International also reports its backlog, or the value of its outstanding orders that have not yet been executed or delivered. ICF International's backlog reached $3.4 billion in the latest quarter. This quarter, ICF International missed Wall Street's estimates and reported a rather uninspiring 7% year-on-year revenue decline, generating $476.2 million of revenue. Looking ahead, sell-side analysts expect revenue to decline by 4.3% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and implies its products and services will face some demand challenges. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. ICF International was profitable over the last five years but held back by its large cost base. Its average operating margin of 7.1% was weak for a business services business. On the plus side, ICF International's operating margin rose by 1.1 percentage points over the last five years, as its sales growth gave it operating leverage. In Q2, ICF International generated an operating margin profit margin of 8.4%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. ICF International's EPS grew at a spectacular 13.6% compounded annual growth rate over the last five years, higher than its 5.9% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into ICF International's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, ICF International's operating margin was flat this quarter but expanded by 1.1 percentage points over the last five years. On top of that, its share count shrank by 2.9%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For ICF International, its two-year annual EPS growth of 11.1% was lower than its five-year trend. We hope its growth can accelerate in the future. In Q2, ICF International reported adjusted EPS at $1.66, down from $1.69 in the same quarter last year. Despite falling year on year, this print beat analysts' estimates by 5.2%. Over the next 12 months, Wall Street expects ICF International's full-year EPS of $7.60 to shrink by 10.8%. Key Takeaways from ICF International's Q2 Results It was encouraging to see ICF International beat analysts' EPS expectations this quarter. On the other hand, its revenue slightly missed. Overall, this was a weaker quarter. The stock traded down 1.5% to $83.01 immediately following the results. Is ICF International an attractive investment opportunity right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
